1. Revenues for the quarter stood at ₹428.4Cr, up 104% from same period previous year
2. EBITDA stood at ₹46.7 Cr translating to EBITDA margins of 10.9%
3. PAT stood at ₹22.5 Cr with PAT margins of 5.3%
4. Undertaking price hikes wherever possible to offset these raw material pressures.
5. This is the first full quarter of consolidation of recent acquisitions of Unitop and Tristar in Rossari’s performance. Both these companies delivered growth during the period, which assisted overall performance.
6. Latest acquisition of Romakk Chemicals has now been consolidated with effect from December 01, 2021. The timely integration of Romakk will further strengthen presence in the textile and Home and Personal Care segment
7. Revenue contribution from the HPPC segment stood at 71%, followed by TS
8. Actively undertaking cross selling opportunities and exploring new geographies
9. Acrylic acid prices last month was 2000$/ton and suddenly this month it has gone up to 2700$/ton
Volatility in raw material prices is expected to continue for next 2 quarters
10. Utilization at dahej stood at 50-60%.
11. For ₹2500 Cr revenue generation, no more additional capex is required, only maintenance capex to continue
12. Q1 is expected an improvement on supply and prices side
13. Volumes are lower on QoQ basis but higher on YoY basis. However major growth is on behalf of hike in prices
14. Antiviral and antimicrobial for textile are more consumer based products catering to large manufactures like Marks&Spencer and others. Towel manufacturers are one of the largest consumer of
these products, however these additives makes up only 5% of composition of final product
Segmental split
HPPC- revenue for this segment stood at ₹305.24 Cr contributing 71% to total revenues. The segment grew 155.2% YoY and 29.3% on a QoQ basis.
The business reported healthy sales supported by stable traction in FMCG, anti-viral & personal hygiene product portfolio volumes
TSC- Revenues for the segment stood at ₹102.8 Cr translation 24% contribution to revenues.
The segment grew 31.5% YoY, however it contracted by (-6.3%) on a QoQ basis. Growth driven by a pickup in demand in domestic and export markets
AHN- Revenues for the segment stood at ₹20.38Cr i.e. contributing 5% to total revenues with growth of 67% YoY. however the segment contracted by (-47.3%) on a QoQ basis. Growth driven by a pickup in demand in domestic and export markets
Product introductions
Introduced new technology i.e. polyester resin
Introduced new green products i,e, green urea and green silicate.
Substitutes for bleach
Introduced lycra protector, water repellents, acrylic polymers etc
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. They were the fastest growing company among the Top 30 companies in the domestic formulations market as per IQVIA. JB grew at 27% vs market growth of 18%.
2. Revenues for the quarter stood at ₹601 Cr (10% growth YoY).
3. EBITDA excluding ESOP cost stood at ₹153 Cr (10.5% decline YoY). Gross margins for the quarter stood at 66% although there was significant cost inflation.
4. Cost pressure persists on raw material and packing material, which is expected to continue in the medium-term.
5. During Q3 FY22, Domestic Formulations business launched 12 new products including Molnupiravir, Cilacar TM, Azovas-T and Pirfenidone.
Watch the video to understand the business details :
1. Revenues for the quarter stood at ₹358 Cr (4.8% growth YoY).
2. Growth was mainly driven by the Formulations business which grew at 18.5% YoY on a constant currency basis whereas the API business declined by 20% YoY driven by logistic challenges and subdued demand for Albendazole.
3. Growth in the API portfolio excluding Albendazole has been strong in the first 9 months. Albendazole demand still remains subdued but there is a strong recovery in demand QoQ.
1. The revenues for Q3FY22 stood at ₹429.4Cr from ₹310.3 Cr in same period previous year accounting to growth of 38.4% YoY
2. EBITDA for the quarter stood at ₹48.5Cr translating to EBITDA margins of 11.29%
3. The contributors to Consolidated Net Profit after tax of ₹106.02Crore in Q3-FY22 include share of profit of DyStar (associate company of Kiri) to the tune of ₹81.49 Crore, and
₹13.44Crore from Lonsen Kiri Chemical Industries Limited
3. Consolidated Gross Margin has strengthened to 33%, a Q-o-Q increase of 3% which is further expected to improve in coming quarters
1. For Q3FY22 revenue was ₹185.8 Cr vs ₹130.4 Cr in Q3FY21 a growth of 42% on YoY basis.
2. Q3 EBITDA was at ₹30.2 Cr as compared to ₹27.3 Cr in the same quarter of the previous year.
3. For 9M FY22 revenue was ₹446.6 Cr vs ₹330.8 Cr in 9MFY21 a growth of 35% on YoY basis.
4. 9MFY22 EBITDA surged by 141% to ₹79.7 Cr as compared to ₹33.1 Cr in 9MFY21.
5. Esports segment recorded revenue of ₹109.3 Cr in Q3FY22 vs ₹57.8 Cr last year in the same quarter, a growth of 89% YoY basis.
Their Gamified early learning segment recorded revenue of ₹47.2Cr.
1. Operating revenue for Q3FY22 was ₹18.3 million compared to ₹11.2 in Q2FY22.
2. Net loss for the Quarter was at ₹29.9 million mainly because of Esop.
3. Portfolio value of investments increased from ₹436.3 million on December 31, 2020 to ₹611.2 million on December 31, 2021.
Business Update
1. Signal Analytics, a wholly owned subsidiary raised ₹52.4 million by way of preferential allotment of Pre Series A. Thereby Xelpmoc shareholding in Signal has changed to 91.95% on a fully diluted basis.